跳至主要内容
临床试验/NCT00977028
NCT00977028Unknown1 期

Tumescent Lidocaine Bioavailability and Absorption Kinetics:Maximum Safe mg/kg Lidocaine Dosage

Klein, Jeffrey A., M.D.1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2005年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
发起方
入组人数
14
试验地点
1
主要终点
Peak or maximum serum lidocaine concentration (Cmax) following a given mg/kg dosage of lidocaine delivered by subcutaneous infiltration of tumescent local anesthesia

研究概览

简要总结

This pharmacokinetic clinical trial is a dose ranging study of lidocaine in tumescent local anesthesia. The goal is to understand the absorption pharmacokinetic of tumescent lidocaine and to determine an objective (statistical) estimate of the maximum safe mg/kg dosage of lidocaine in tumescent local anesthesia without liposuction.

详细描述

Background:

Tumescent local anesthesia (TLA) permits a wide variety of therapeutic surgical procedures of subcutaneous tissues and skin to be performed totally by local anesthesia ( ). Infiltration of a sufficient volume of TLA causes the target tissues become temporarily tumescent, or swollen and firm.

TLA is defined as the subcutaneous infiltration of a large volume of a tumescent local anesthetic solution (TLAS). The safe use of TLA requires the safe formulation and safe use of a tumescent local anesthetic solution (TLAS). By definition TLAS contains very dilute lidocaine (≤ 1 gm/liter = 0.1%) and epinephrine (≤ 1 mg/liter = 1:1,000,000) with sodium bicarbonate (10 milliequivalents/liter) in a physiologic crystalloid solution. Bicarbonate, an essential ingredient, neutralizes the acid pH of commercial lidocaine and epinephrine thereby eliminating the intense stinging discomfort which often associated with the infiltration of commercial local anesthetics. Lidocaine which has been infiltrated for TLA is referred to as tumescent lidocaine.

The FDA-approved maximum recommended dosage is 7 mg/kg for lidocaine with epinephrine infiltration local anesthesia. However with TLA much larger mg/kg dosages of lidocaine are used. The safety and efficacy of TLA is based on the unexpected slow lidocaine absorption associated with large volumes of very dilute lidocaine and epinephrine when infiltrated into subcutaneous tissue. Published estimates of a maximum safe mg/kg dosage of tumescent lidocaine are derived from liposuction patients and have ranged from 35 mg/kg to 55 mg/kg ( ) and much higher lidocaine doses without evident toxicity have been reported.

Liposuction, a cosmetic surgical procedure which removes subcutaneous fat, also removes some tumescent lidocaine thereby reducing lidocaine bioavailability. In contrast, therapeutic surgeries usually do not remove subcutaneous lidocaine and therefore the bioavailability of lidocaine is relatively increased as is the peak serum lidocaine concentration (Cmax) and the risk of lidocaine toxicity. Because TLA is now used for surgical procedures unrelated to liposuction, it is desirable to have a reliable estimate of the maximum safe dosage of tumescent lidocaine based on clinical data from subjects not having liposuction.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 72 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Healthy female (ASA class 1 or 2)
  • Desires liposuction
  • Easily accessible veins

排除标准

  • History of Hepatitis C, HIV
  • ASA class greater or equal to 3

研究组 & 干预措施

Tumescent Lidocaine with liposuction

Experimental

Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction

干预措施: Tumescent Local Anesthesia (lidocaine, epinephrine) (Drug)

Tumescent Lidocaine with liposuction

Experimental

Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction

干预措施: Liposuction (Procedure)

Tumescent Lidocaine No Liposuction

Experimental

Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction

干预措施: Tumescent Local Anesthesia (lidocaine, epinephrine) (Drug)

Tumescent Lidocaine No Liposuction

Experimental

Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction

干预措施: Liposuction (Procedure)

结局指标

主要结局

Peak or maximum serum lidocaine concentration (Cmax) following a given mg/kg dosage of lidocaine delivered by subcutaneous infiltration of tumescent local anesthesia

时间窗: 24 hours

次要结局

  • Cmax following 45mg/kg tumescent lidocaine has a Normal distribution. We define the probability that Cmax exceeds 6 microgram/ml, the toxic threshold for lidocaine as a function of lidocaine dosage.(24 hours)

研究者

发起方
Klein, Jeffrey A., M.D.
申办方类型
Indiv

研究点 (1)

Loading locations...

相似试验